Could a lower HIV drug dose work just as well?

NCT ID NCT02384967

Completed Disease control Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a lower daily dose of the HIV drug darunavir (400 mg instead of 800 mg) can keep the virus suppressed in people whose HIV is already well-controlled. The trial involved 100 adults with HIV who had undetectable viral loads for at least a year. The goal was to see if the reduced dose could maintain viral suppression for 48 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: darunavir (a lower dose of 400 mg per day instead of the usual 800 mg)
What this could lead to: If successful, this could allow some people with HIV to take a lower dose of darunavir while still keeping the virus under control, potentially reducing side effects and costs.
What could go wrong: This is a small, early-phase trial (Phase 2) with only 100 participants. It is not yet proven that the lower dose works as well as the standard dose, and there is a risk of the virus becoming detectable again.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTION

Contacts and locations

Locations

Hôpital Saint Louis

Paris, 75010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.